drugset / Trial / NCT02036580

D2212C00002 J-Phase II Study

NCT02036580

Phase 2 Completed 37 enrolled AstraZeneca MedImmune LLC · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to evaluate the safety and tolerability of multiple-doses of tralokinumab in Japanese patients with Idiopathic Pulmonary Fibrosis.

Timeline

Start
2014-01
Primary completion
2015-11
Completion
2015-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Tralokinumab Monoclonal antibody